The past few years have been challenging for me, my family, and especially my youngest daughter, Bella, who in 2017 was diagnosed at 9 years old with neuromyelitis optica spectrum disorder (NMOSD). At the time, the best course of therapy recommended by Bella’s neurologist was Rituxan…

Ad Scientiam is developing new digital biomarkers of neuromyelitis optica spectrum disorder (NMOSD) that may allow continuous and remote monitoring of patients’ symptoms over time. The Paris-based software company announced the program launch along with a similar one for people with generalized myasthenia gravis, another rare autoimmune…

People with neuromyelitis optica spectrum disorder (NMOSD) who experience relapses are three times more likely to change their treatment regimen than those who have no relapses, a study found. Researchers also observed that people who experienced optic neuritis with or without brain symptoms, those with shorter disease duration, and…

For nearly two and a half years, I avoided catching the COVID-19 virus. When I finally ventured away from my home, I was infected. Weeks later, I’m still feeling the effects. My daughter, Sophie, was recently given an opportunity to represent Canada at a global dance competition in Portugal.

I still remember the feeling of despair I had while sitting on a cool stretcher in the neurologist’s office, after hearing devastating news about my health. The neurologist admitted that he had no idea what I had, but he assured me it was a severe condition. I wondered why after…

An improved understanding of the biological processes that drive neuromyelitis optica spectrum disorder (NMOSD) has led to treatment advancements in recent years. In a presentation at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2021, Sean Pittock, MD, director of the Mayo Clinic’s Center for…